Profile data is unavailable for this security.
About the company
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
- Revenue in USD (TTM)130.00k
- Net income in USD-18.59m
- Incorporated2017
- Employees12.00
- LocationSerina Therapeutics Inc601 Genome Way,, Suite 2001HUNTSVILLE 35806United StatesUSA
- Phone+1 (256) 327-9630
- Websitehttps://serinatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lunai Bioworks Inc | 0.00 | -130.98m | 17.21m | 29.00 | -- | -- | -- | -- | -7.51 | -7.51 | 0.00 | -0.5626 | 0.00 | -- | -- | 0.00 | -203.39 | -75.79 | -304.47 | -85.18 | -- | -- | -- | -- | -- | -28.85 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
| IN8bio Inc | 0.00 | -20.66m | 17.38m | 18.00 | -- | 0.6194 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 17.40m | 2.00 | -- | 7.38 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 17.76m | 5.00 | -- | 0.9701 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.97m | 13.00 | -- | 0.5644 | -- | 36.21 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 19.52m | 12.00 | -- | -- | -- | 150.12 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 19.54m | 2.00 | -- | 2.48 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 19.89m | 4.00 | -- | 345.16 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 19.92m | 6.00 | -- | -- | -- | 56.85 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Vistagen Therapeutics Inc | 736.00k | -62.24m | 20.03m | 59.00 | -- | 0.2964 | -- | 27.22 | -1.91 | -1.91 | 0.0227 | 1.71 | 0.008 | -- | -- | 13,142.86 | -67.86 | -55.19 | -76.71 | -59.56 | -- | -- | -8,455.98 | -5,842.62 | -- | -- | 0.0098 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.52m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 20.75m | 26.00 | -- | 2.28 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.36m | 18.00 | -- | 1.50 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 21.57m | 7.00 | -- | 2.45 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.78m | 7.00 | -- | 0.7632 | -- | 1.39 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 21.84m | 13.00 | -- | -- | -- | 2.57 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Serina Therapeutics Inc's reporting currency: US Dollar USD
4.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 159.14k | 1.49% |
| Broadwood Capital, Inc.as of 30 Sep 2025 | 83.20k | 0.78% |
| Waverly Advisors LLC (Alabama)as of 30 Sep 2025 | 67.49k | 0.63% |
| Geode Capital Management LLCas of 31 Dec 2025 | 30.41k | 0.29% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 20.51k | 0.19% |
| Linscomb Wealth, Inc.as of 31 Dec 2025 | 18.80k | 0.18% |
| Keel Point LLCas of 31 Dec 2025 | 17.77k | 0.17% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 16.59k | 0.16% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 14.54k | 0.14% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 12.76k | 0.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
